July 5, 2018

Senator Cory A. Booker  Representative Rosa DeLauro
359 Dirksen Senate Office Bldg  2413 Rayburn House Office Bldg
Washington, DC    Washington, DC

Re: Access to Infertility Treatment and Care Act (S. 2960/H.R. 5965)

Dear Senator Booker and Representative DeLauro:

On behalf of the Endocrine Society, I am pleased to offer our support for the Access to Infertility Treatment and Care Act (S. 2960/H.R. 5965). The Endocrine Society is the world’s largest professional organization of endocrinologists, representing the interests of over 18,000 clinicians and scientists engaged in the treatment and research of endocrine disorders. Many of our members engage in research on and treatment of infertility, as hormone disorders are a major cause of infertility.

As you know, infertility affects 1 in 8 couples, often because of chronic conditions, diseases of the endocrine system, structural problems within the reproductive system, or treatment for other diseases such as cancer. Unfortunately, many insurance plans do not offer coverage for infertility treatments, cryopreservation, or adoption, leaving those affected to pay the high costs of treatments and/or adoption out-of-pocket. This legislation builds upon existing laws and ensures that all Americans who need and want infertility treatment services have access to them.

Through review of the legislation, we would like to offer the following suggestions to clarify and/or build on the services already covered in the legislation.

- More than 50% of cancer patients who elect to undergo fertility preservation require cryopreservation of eggs or sperm. As such, we ask that you consider including iatrogenic “elective fertility preservation” which can include cryopreservation of eggs, sperm or embryos.
- Many women and/or couples must undergo multiple IVF cycles before achieving success. We ask that you clarify the number of repeat treatments that insurers must cover or whether insurers will have the option to place a different limitation on services used. We support the highest allowance for repeat treatments as possible.

Thank you for your leadership on this important issue. If we can provide any additional information or support, please contact Stephanie Kutler, Director, Advocacy & Policy at skutler@endocrine.org.

Sincerely,

Susan Mandel, MD
President, Endocrine Society